NCT02811198Completed
Pain, Reward, Attention and Neurocircuitry: Biomarkers of Suicidality
Source: ClinicalTrials.gov · Last updated 27 Feb 2026
Brief summary (registry, in English)
The ultimate aim of this study is to identify a biomarker of suicide risk in MDD by measuring the "hedonic spectrum" (pain and reward responsivity), attention and its associated brain structures using brain scans (fMRI and DTI), as well as the stability of markers over time.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 97 (actual)
- First submitted
- 20 Jun 2016
- Start date
- 1 Jan 2017
- Primary completion date
- 9 Dec 2024
- Lead sponsor
- Unity Health Toronto
- Diseases
- Depression
- NCT number
- NCT02811198
What you commit to
- Study type: Observational
- Participants enrolled: 97
- From 1 Jan 2017 to the primary completion date, 9 Dec 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Individuals who are taking a daily sedative hypnotic, atypical antipsychotic or stimulant must be on a stable dose for at least 4 weeks prior to the neuroimaging scan. The dose must not be taken after 10:00pm the evening prior to the scan. Those receiving a benzodiazepine or an atypical antipsychotic on an "as needed" basis (taken, but not every day) will be washed out of their benzodiazepine/atypical antipsychotic for two weeks prior to neuroimaging. Those receive stimulants on an "as needed" basis will be washed out for 1-3 days prior to neuroimaging, depending on the stimulant half-life.
Other illness
- Medical condition requiring immediate investigation or treatment
- Recent (\< 6 months)/current history of drug abuse/dependence (other than caffeine, or nicotine)
- Lifetime history of psychosis, Bipolar I or Bipolar II; other Axis I comorbidities are allowable
Other
- Pregnancy/lactation
- Participation in experimental treatment trials for the study duration.
Who the study is looking for
- DSM-5 criteria for Major Depressive Episode within a MDD, confirmed through MINI diagnosis104
- Ages between 18 and 70 years
- Hamilton Depression Rating Scale - 17 item (HAMD-17) \>= 14
- Capable of giving informed consent
- Groups 1 and 2 participants only: HAMD-17 item 3 (suicide) \>= 2
- Group 2 participants only: positive history of a suicide attempt within the last six months
- Group 3 participants only: positive history of a lifetime suicide attempt
Age in the registry: 18 years to 70 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sakina Rizvi Coordinator of this site? Confirm its status | Toronto | Canada | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.